Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence study of TRS003 vs bevacizumab with paclitaxel-carboplatin in advanced non-squamous non-small cell lung cancer
ChiCTR1900024463Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of RPH-001 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
RPH-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900024463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024463.